All lobbying filings
SANDOZ INC
SANDOZ INC filed a Q3 report for SANDOZ INC on October 20, 2026.
Lobbying for SANDOZ INC · Pharmaceutical company
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$170,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
New Jersey
Government bodies contacted
6
Lobbying activity
1
Policies related to Medicare coverage and reimbursement of biosimilars Promoting a resilient pharmaceutical supply chain Policies related to serial patent litigation under the Hatch-Waxman Act. Issues related to increasing access to generic and biosimilar medications